Sean MD - Sera Prognostics CoFounder Board
| SERA Stock | USD 6.11 0.08 1.33% |
Insider
Sean MD is CoFounder Board of Sera Prognostics
| Address | 2749 East Parleys Way, Salt Lake City, UT, United States, 84109 |
| Phone | 801 990 0520 |
| Web | https://seraprognostics.com |
Sera Prognostics Management Efficiency
The company has return on total asset (ROA) of (0.2666) % which means that it has lost $0.2666 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4958) %, meaning that it created substantial loss on money invested by shareholders. Sera Prognostics' management efficiency ratios could be used to measure how well Sera Prognostics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.59. At present, Sera Prognostics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 1.4 M, whereas Total Assets are forecasted to decline to about 87.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Snyder | Personalis | N/A | |
| Michael Biehl | Sotera Health Co | 68 | |
| John West | Personalis | 67 | |
| Debra Zack | Exagen Inc | 65 | |
| Yusheng Han | Burning Rock Biotech | 45 | |
| Zhihong Zhang | Burning Rock Biotech | 48 | |
| Marcel Konrad | Caredx Inc | 48 | |
| Atul Butte | Personalis | N/A | |
| Shaokun Chuai | Burning Rock Biotech | 45 | |
| Robert Hauzie | Sotera Health Co | N/A | |
| Dov Oppenheim | DarioHealth Corp | N/A | |
| MingChou Lee | Exagen Inc | N/A | |
| Carol Tillis | Personalis | N/A | |
| Richard Anderson | DarioHealth Corp | 55 | |
| Sasha MBA | Caredx Inc | 38 | |
| Mickey MD | Caredx Inc | N/A | |
| Charles IV | Psychemedics | 58 | |
| Werner Baumgartner | Psychemedics | N/A | |
| Sarah Ashby | Psychemedics | N/A | |
| Jinxiang Li | Burning Rock Biotech | 39 | |
| DPHIL FRCP | Personalis | 50 | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.27 |
Sera Prognostics Leadership Team
Elected by the shareholders, the Sera Prognostics' board of directors comprises two types of representatives: Sera Prognostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sera. The board's role is to monitor Sera Prognostics' management team and ensure that shareholders' interests are well served. Sera Prognostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sera Prognostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Benjamin JD, General Counsel | ||
| Steven Graves, CoFounder Board | ||
| Sean MD, CoFounder Board | ||
| MS MD, Executive Director | ||
| John Boniface, Chief Officer | ||
| Paul Kearney, Chief Officer | ||
| Evguenia MBA, CEO President | ||
| MBA MBA, Chief Officer | ||
| Michael MD, Chief Officer | ||
| Robert Harrison, Chief Officer | ||
| Nadia Altomare, Chief Officer | ||
| Austin Aerts, Chief Officer |
Sera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sera Prognostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (305.59) % | ||||
| Current Valuation | 157.7 M | ||||
| Shares Outstanding | 32.8 M | ||||
| Shares Owned By Insiders | 11.90 % | ||||
| Shares Owned By Institutions | 71.57 % | ||||
| Number Of Shares Shorted | 1.04 M | ||||
| Price To Book | 3.78 X | ||||
| Price To Sales | 2,195 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sera Prognostics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sera Prognostics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sera Prognostics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sera Prognostics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sera Prognostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Sera Stock refer to our How to Trade Sera Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sera Prognostics. If investors know Sera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sera Prognostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 0.003 | Quarterly Revenue Growth (0.31) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Sera Prognostics is measured differently than its book value, which is the value of Sera that is recorded on the company's balance sheet. Investors also form their own opinion of Sera Prognostics' value that differs from its market value or its book value, called intrinsic value, which is Sera Prognostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sera Prognostics' market value can be influenced by many factors that don't directly affect Sera Prognostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sera Prognostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sera Prognostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sera Prognostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.